More Mungati1, Anna Machiha, Owen Mugurungi, Mufuta Tshimanga, Peter H Kilmarx, Justice Nyakura, Gerald Shambira, Vitalis Kupara, David A Lewis, Elizabeth Gonese, Beth A Tippett Barr, H Hunter Handsfield, Cornelis A Rietmeijer. 1. From the *Zimbabwe Ministry of Health and Child Care; †Department of Community Medicine, University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; ‡US Centers for Disease Control and Prevention, Zimbabwe and Division of Global HIV/AIDS, CDC, Atlanta, GA; §Fogarty International Center, National Institutes of Health, Bethesda, MD; ¶Zimbabwe Community Health Intervention Research (ZiCHIRe) Project, Harare, Zimbabwe; ∥Western Sydney Sexual Health Centre, Parramatta; **Marie Bashir Institute for Infectious Diseases and Biosecurity & Sydney Medical School-Westmead, University of Sydney, Sydney, New South Wales, Australia; ††School of Medicine, University of Washington, Seattle, WA; ‡‡Colorado School of Public Health, University of Colorado Denver, Denver, CO; §§Rietmeijer Consulting LLC, Denver, CO.
Abstract
BACKGROUND: In many countries, sexually transmitted infections (STIs) are treated syndromically. Thus, patients diagnosed as having genital ulcer disease (GUD) in Zimbabwe receive a combination of antimicrobials to treat syphilis, chancroid, lymphogranuloma venereum (LGV), and genital herpes. Periodic studies are necessary to assess the current etiology of GUD and assure the appropriateness of current treatment guidelines. MATERIALS AND METHODS: We selected 6 geographically diverse clinics in Zimbabwe serving high numbers of STI cases to enroll men and women with STI syndromes, including GUD. Sexually transmitted infection history and risk behavioral data were collected by questionnaire and uploaded to a Web-based database. Ulcer specimens were obtained for testing using a validated multiplex polymerase chain reaction (M-PCR) assay for Treponema pallidum (TP; primary syphilis), Haemophilus ducreyi (chancroid), LGV-associated strains of Chlamydia trachomatis, and herpes simplex virus (HSV) types 1 and 2. Blood samples were collected for testing with HIV, treponemal, and nontreponemal serologic assays. RESULTS: Among 200 GUD patients, 77 (38.5%) were positive for HSV, 32 (16%) were positive for TP, and 2 (1%) were positive for LGV-associated strains of C trachomatis. No H ducreyi infections were detected. No organism was found in 98 (49.5%) of participants. The overall HIV positivity rate was 52.2% for all GUD patients, with higher rates among women compared with men (59.8% vs 45.2%, P < 0.05) and among patients with HSV (68.6% vs 41.8%, P < 0.0001). Among patients with GUD, 54 (27.3%) had gonorrhea and/or chlamydia infection. However, in this latter group, 66.7% of women and 70.0% of men did not have abnormal vaginal or urethral discharge on examination. CONCLUSIONS: Herpes simplex virus is the most common cause of GUD in our survey, followed by T. pallidum. No cases of chancroid were detected. The association of HIV infections with HSV suggests high risk for cotransmission; however, some HSV ulcerations may be due to HSV reactivation among immunocompromised patients. The overall prevalence of gonorrhea and chlamydia was high among patients with GUD and most of them did not meet the criteria for concomitant syndromic management covering these infections.
BACKGROUND: In many countries, sexually transmitted infections (STIs) are treated syndromically. Thus, patients diagnosed as having genital ulcer disease (GUD) in Zimbabwe receive a combination of antimicrobials to treat syphilis, chancroid, lymphogranuloma venereum (LGV), and genital herpes. Periodic studies are necessary to assess the current etiology of GUD and assure the appropriateness of current treatment guidelines. MATERIALS AND METHODS: We selected 6 geographically diverse clinics in Zimbabwe serving high numbers of STI cases to enroll men and women with STI syndromes, including GUD. Sexually transmitted infection history and risk behavioral data were collected by questionnaire and uploaded to a Web-based database. Ulcer specimens were obtained for testing using a validated multiplex polymerase chain reaction (M-PCR) assay for Treponema pallidum (TP; primary syphilis), Haemophilus ducreyi (chancroid), LGV-associated strains of Chlamydia trachomatis, and herpes simplex virus (HSV) types 1 and 2. Blood samples were collected for testing with HIV, treponemal, and nontreponemal serologic assays. RESULTS: Among 200 GUD patients, 77 (38.5%) were positive for HSV, 32 (16%) were positive for TP, and 2 (1%) were positive for LGV-associated strains of C trachomatis. No H ducreyi infections were detected. No organism was found in 98 (49.5%) of participants. The overall HIV positivity rate was 52.2% for all GUD patients, with higher rates among women compared with men (59.8% vs 45.2%, P < 0.05) and among patients with HSV (68.6% vs 41.8%, P < 0.0001). Among patients with GUD, 54 (27.3%) had gonorrhea and/or chlamydia infection. However, in this latter group, 66.7% of women and 70.0% of men did not have abnormal vaginal or urethral discharge on examination. CONCLUSIONS: Herpes simplex virus is the most common cause of GUD in our survey, followed by T. pallidum. No cases of chancroid were detected. The association of HIV infections with HSV suggests high risk for cotransmission; however, some HSV ulcerations may be due to HSV reactivation among immunocompromised patients. The overall prevalence of gonorrhea and chlamydia was high among patients with GUD and most of them did not meet the criteria for concomitant syndromic management covering these infections.
Authors: C Y Chen; R C Ballard; C M Beck-Sague; Y Dangor; F Radebe; S Schmid; J B Weiss; V Tshabalala; G Fehler; Y Htun; S A Morse Journal: Sex Transm Dis Date: 2000-01 Impact factor: 2.830
Authors: David A Lewis; Etienne Müller; Lisa Steele; Maya Sternberg; Frans Radebe; Michael Lyall; Ronald C Ballard; Gabriela Paz-Bailey Journal: Sex Transm Dis Date: 2012-11 Impact factor: 2.830
Authors: Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Katharine J Looker; Amalia S Magaret; Margaret T May; Katherine M E Turner; Peter Vickerman; Sami L Gottlieb; Lori M Newman Journal: PLoS One Date: 2015-10-28 Impact factor: 3.240
Authors: N Saman Wijesooriya; Roger W Rochat; Mary L Kamb; Prasad Turlapati; Marleen Temmerman; Nathalie Broutet; Lori M Newman Journal: Lancet Glob Health Date: 2016-08 Impact factor: 26.763
Authors: Z Mike Chirenje; Nicholas Dhibi; H Hunter Handsfield; Elizabeth Gonese; Beth Tippett Barr; Lovemore Gwanzura; Ahmed S Latif; Dumisili Venessa Maseko; Ranmini S Kularatne; Mufuta Tshimanga; Peter H Kilmarx; Anna Machiha; Owen Mugurungi; Cornelis A Rietmeijer Journal: Sex Transm Dis Date: 2018-06 Impact factor: 2.830
Authors: Cornelis A Rietmeijer; More Mungati; Peter H Kilmarx; Beth Tippett Barr; Elizabeth Gonese; Ranmini S Kularatne; David A Lewis; Jeffrey D Klausner; Luanne Rodgers; H Hunter Handsfield Journal: Sex Transm Dis Date: 2019-09 Impact factor: 2.830
Authors: Teodora Ec Wi; Francis J Ndowa; Cecilia Ferreyra; Cassandra Kelly-Cirino; Melanie M Taylor; Igor Toskin; James Kiarie; Nancy Santesso; Magnus Unemo Journal: J Int AIDS Soc Date: 2019-08 Impact factor: 5.396
Authors: Avi J Hakim; Chelsea Iwamoto; Steven G Badman; Barne Willie; Simon Pekon; Herick Aeno; Ruthy Neo-Boli; Sophie Ase; Damian Weikum; Andrew J Vallely; Angela Kelly-Hanku Journal: Sex Transm Dis Date: 2021-02-01 Impact factor: 3.868
Authors: Katharine Jane Looker; Christine Johnston; Nicky J Welton; Charlotte James; Peter Vickerman; Katherine M E Turner; Marie-Claude Boily; Sami L Gottlieb Journal: BMJ Glob Health Date: 2020-03-08